J.P. Morgan analyst Cory Kasimov maintained a Buy rating on GW Pharma (GWPH) on January 8. The company’s shares closed yesterday at $119.54.
According to TipRanks.com, Kasimov is a 2-star analyst with an average return of -0.2% and a 38.7% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Allogene Therapeutics Inc, and Global Blood Therapeutics.
Currently, the analyst consensus on GW Pharma is a Strong Buy with an average price target of $178.71.
See today’s analyst top recommended stocks >>
The company has a one-year high of $179.65 and a one-year low of $90.14. Currently, GW Pharma has an average volume of 505K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its lead cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex.
Read More on GWPH:
